Key result
A 58-year-old woman developed stage IV congestive heart failure 7 years after completing doxorubicin treatment for ovarian carcinoma, with occult dysfunction detected 6 years prior.
Why the study?
Can doxorubicin treatment lead to late-onset congestive heart failure in adult patients?
Case Report (n=1)
Can doxorubicin treatment lead to late-onset congestive heart failure in adult patients?
This case highlights the rare occurrence of late-onset clinical congestive heart failure in an adult years after doxorubicin therapy, emphasizing the potential value of long-term cardiac monitoring.
Answers are grounded in this paper and cite their sources.
Late doxorubicin exposure may cause very late HF; leaves open optimal long-term monitoring strategies.
The occurrence of late congestive heart failure (CHF) as the first clinical manifestation of doxorubicin-induced cardiac toxicity is unusual in children and very rare in adults. However, subclinical cardiac dysfunction is commonly detected in children years after treatment with doxorubicin containing regimens. We report a 58 year old woman who developed stage IV CHF 7 years after completion of doxorubicin treatment for carcinoma of the ovary. Occult cardiac dysfunction was first demonstrated by radionuclide angiography 6 years prior to the occurrence of the clinical manifestations. This unique course of the disease and the management of the CHF are discussed.
No takes yet. Share an insight, caveat, or question.
Lishner et al. (1992) conducted a case report in Late doxorubicin cardiotoxicity (n=1). Doxorubicin was evaluated on Development of stage IV congestive heart failure. A 58-year-old woman developed stage IV congestive heart failure 7 years after completing doxorubicin treatment for ovarian carcinoma, with occult dysfunction detected 6 years prior.
Synapse has enriched 10 related papers. Consider them for comparative context: